Viveve to Present at the Ladenburg Thalmann 2017 Healthcare Conference
ENGLEWOOD, CO -- (Marketwired) -- 09/19/17 -- Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that Patricia Scheller, chief executive officer, will present at the 2017 Ladenburg Thalmann Healthcare Conference, on Tuesday, September 26th at 9:30AM ET in New York City. Ms. Scheller will provide an update of the Company's global development and commercialization of the GENEVEVE™ Treatment and InControl Products by Viveve.
|Event:||2017 Ladenburg Thalmann Healthcare Conference|
|Date:||September 26, 2017|
|Time:||9:30 - 9:55 AM ET|
Ms. Scheller and Scott Durbin, Viveve's chief financial officer, will be meeting with members of the investment community during one-on-one meetings at the conference. A live audio webcast of the presentation will be available on the "Investors" section of the Company's website at ir.viveve.com. Interested parties unable to listen to the live webcast can access an archived version on the Company's website for approximately 90 days.
Viveve Medical, Inc. is a women's health and wellness company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the GENEVEVE™ treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) energy-based technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in one 30-minute in-office session.
International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications from over 50 countries. Consistent with these approvals, Viveve has submitted an IDE to the FDA to conduct a pivotal study on use of the device for improvement in sexual function. Currently, in the United States, the Viveve System is cleared by the FDA for general surgical procedures for electrocoagulation and hemostasis.
InControl Products by Viveve are FDA cleared medical devices that treat stress, urge, and mixed incontinence conditions and products to improve pelvic floor strength. Viveve exclusively distributes InControl Medical's products to healthcare providers in the United States.
For more information visit Viveve's website at www.viveve.com.
Safe Harbor Statement
All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Viveve is a registered trademark of Viveve, Inc.
Geneveve is a trademark of Viveve, Inc.
Investor Relations contact:
Stern Investor Relations, Inc.
1270 Avenue of the Americas, Suite 408
New York, NY 10020
Berry & Company Public Relations
Source: Viveve Medical, Inc.
Released September 19, 2017